Application
|
lens fragmentation |
---|---|
Phaco energy emitted
|
none
|
Cataract range
|
suitable for any grade cataract
|
Material
|
memory shaped super-elastic thin nitinol filament
|
Length
|
~15 cm
|

ZEISS miLOOP Removing the challenge of dense cataracts.
The miLOOP® from ZEISS is a game-changing microinterventional lens fragmentation device which is designed to remove the challenges of hard cataracts. Using micro-thin super-elastic, self-expanding nitinol filament technology, the ZEISS miLOOP allows cataract surgeons to achieve zero-energy lens fragmentation for any grade cataract.1
Product availability check
To find out if this product is available in your country, please contact us.
Our team will get back to you with all the details.

Significantly reduce overall phaco energy and fluid use for dense cataracts
A randomized controlled study in the British Journal of Ophthalmology showed that using ZEISS miLOOP in hard grade 3-4+ nuclear cataracts reduces phaco energy by up to 53% and therefore also ultrasonic vibrations. The same study also confirms that using ZEISS miLOOP significantly lowers the surgical irrigation fluid volume used per case by up to 30%.1

Apply minimal stress to the capsule and zonules
ZEISS miLOOP is engineered to minimize capsular and zonular stress. It allows out-in nucleus disassembly that directs the force used to divide the lens inwards, while conventional techniques employ in-out lens cutting with adjunct phaco-energy.1

Reduced procedure time and easier cortical cleanup
In a 2019 surgeon survey, the majority of trained ZEISS miLOOP surgeons report a perceived reduction in overall procedure time with ZEISS miLOOP.2 Furthermore, 84% of the surgeons report an easier cortical cleanup during irrigation/aspiration with the use of ZEISS miLOOP. 2
Specifications
ZEISS miLOOP
Get in touch with us!
Receive more information about the product and availability in your country!
-
1
Ianchulev T, Chang DF, Koo E, et al Microinterventional endocapsular nucleus disassembly: novel technique and results of first-in-human randomised controlled study. British Journal of Ophthalmology April 2018.
-
2
internal user survey, n=279, lantech Data Analytics 20190708 PPT, data on file